BL-1020

Edit links
Source: Wikipedia, the free encyclopedia.
BL-1020
Identifiers
  • 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
JSmol)
  • C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN
  • InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2
  • Key:BABFYCSPNDKXRI-UHFFFAOYSA-N

BL-1020 (

GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.[1] In March 2013, it went into the II/III trial phase.[2] It has been introduced by BioLineRx
, a biopharmaceutical development company.

References

  1. PMID 23059159
    .
  2. ^ Biolinerx (Jan 7, 2013). "BioLineRx to Announce Interim Results of Phase II/III Trial for Schizophrenia Drug during week of March 18, 2013". Biolinerx. Archived from the original on 2013-03-03.
Retrieved from "https://en.wikipedia.org/w/index.php?title=BL-1020&oldid=1120071972"